Hyperphosphatemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 - ResearchAndMarkets.com

December 19, 2018
The “Hyperphosphatemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The ‘Hyperphosphatemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018’ report provides comprehensive insights about marketed and Phase III products for Hyperphosphatemia. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Hyperphosphatemia

Coverage of API manufacturers for Hyperphosphatemia marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Hyperphosphatemia

This report provides a comprehensive understanding of the emerging Phase III therapies for Hyperphosphatemia which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Hyperphosphatemia: Overview

Risk FactorsCausesSymptomsPathophysiologyPrognosisDiagnosisTreatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

Product DescriptionRoute of SynthesisMechanism of ActionPharmacologyPharmacodynamicsPharmacokineticsAdverse ReactionsClinical TrialsRegulatory MilestonesProduct Development ActivitiesUnited StatesEuropeHistorical Global SalesForecasted Global Sales

5. Emerging Therapies (Phase III)

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hs5m9z/hyperphosphatemia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005259/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs ,Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/19/2018 04:28 AM/DISC: 12/19/2018 04:27 AM


Update hourly